{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:28:15Z","timestamp":1790220495277,"version":"4.1.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Psoriasis impacts psychological and quality-of-life (QoL). While biologic therapies demonstrated robust efficacy in reducing skin lesions, their broader psychosocial impact remains underexplored in real-world settings. This ambispective observational cohort study evaluated clinical, psychological, and health-related QoL (HRQoL) outcomes of biologic therapy in patients with moderate-to-severe plaque psoriasis treated in routine dermatological practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 133 patients undergoing biologic therapy at a referral center in Northern Italy were assessed. Baseline data (T0) were retrospectively extracted from medical records, while 6-month follow-up assessments (T1) were conducted prospectively. Clinical severity (PASI), depression (PHQ-9, BSI-18), anxiety and somatization (BSI-18), perceived stress (PSS), dermatology-specific QoL (DLQI), and general HRQoL (WHOQOL-BREF) were evaluated. Regression models identified baseline predictors of T1 psychological and QoL outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At follow-up, patients reported significant improvements in psychological wellbeing and QoL. PHQ-9 scores decreased markedly (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001), with the prevalence of moderate-to-severe depressive symptoms dropping from 28.6% to 5.3%. Substantial perceived stress (PSS \u2265 27) declined from 15.0% to 1.5%. DLQI scores showed a large effect size (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001), with 89.5% reporting minimal impact (DLQI 0\u20131) at follow-up. Regression analyses identified baseline psychological symptoms as the strongest predictors of follow-up psychological and QoL outcomes. Additional predictors included PASI, female sex, psychiatric comorbidity, and previous biologic therapy. At T1, 77.4% achieved complete skin clearance (PASI 100).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Biologic therapies confer multidimensional benefits in moderate-to-severe psoriasis, extending beyond skin clearance to substantial reductions in psychological distress and improvements in QoL. These findings support a patient-centered model integrating dermatologic and mental health care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyg.2026.1735777","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:37:50Z","timestamp":1770964670000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["From skin clearance to psychological wellbeing: real-world outcomes of biologic therapy in psoriasis"],"prefix":"10.3389","volume":"17","author":[{"given":"Francesco","family":"Cuniberti","sequence":"first","affiliation":[{"name":"Clinical Psychology Unit, \u201cRita Levi Montalcini\u201d Department of Neuroscience, University of Turin","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Miniotti","sequence":"additional","affiliation":[{"name":"Clinical Psychology Unit, \u201cRita Levi Montalcini\u201d Department of Neuroscience, University of Turin","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagiulia","family":"Bailon","sequence":"additional","affiliation":[{"name":"Clinical Psychology Unit, \u201cRita Levi Montalcini\u201d Department of Neuroscience, University of Turin","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mastorino","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Department of Medical Sciences, University of Turin","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Ortoncelli","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Department of Medical Sciences, University of Turin","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Picardi","sequence":"additional","affiliation":[{"name":"Center for Behavioral Sciences and Mental Health, Italian National Institute of Health","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Department of Medical Sciences, University of Turin","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Leombruni","sequence":"additional","affiliation":[{"name":"Clinical Psychology Unit, \u201cRita Levi Montalcini\u201d Department of Neuroscience, University of Turin","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e13864","DOI":"10.1111\/dth.13864","article-title":"Psoriasis affects self-perception of stress negatively: A prospective, case-control study.","volume":"33","author":"Akta\u015f Karabay","year":"2020","journal-title":"Dermatol. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s13555-022-00760-8","article-title":"Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: A systematic literature review and a network meta-analysis.","volume":"12","author":"Armstrong","year":"2022","journal-title":"Dermatol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.4103\/0019-5545.70992","article-title":"Relevance of psychiatry in dermatology: Present concepts.","volume":"52","author":"Basavaraj","year":"2010","journal-title":"Indian J. Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3899\/jrheum.181471","article-title":"Association between comorbidities and quality of life in psoriatic arthritis: Results from a multicentric cross-sectional study.","volume":"47","author":"Bavi\u00e8re","year":"2020","journal-title":"J. Rheumatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1007\/s13555-024-01257-2","article-title":"Impact of disease burden of patients with psoriasis on biologic therapy switching: Real-world evidence from the CorEvitas psoriasis registry.","volume":"14","author":"Blauvelt","year":"2024","journal-title":"Dermatol. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2307\/2136404","article-title":"A global measure of perceived stress.","volume":"24","author":"Cohen","year":"1983","journal-title":"J. Health Soc. Behav."},{"key":"B7","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1089\/whr.2021.0124","article-title":"The CANOVA study real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: A gender perspective.","volume":"3","author":"Colombo","year":"2022","journal-title":"Women\u2019s Health Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/bdi.13392","article-title":"Breaking tradition: A case report on successfully treating psoriasis in a patient with bipolar disorders using biologics, without discontinuing lithium.","volume":"26","author":"Cuniberti","year":"2024","journal-title":"Bipolar Disord."},{"key":"B9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/bs.acc.2020.04.004","article-title":"Cytokines in psoriasis.","volume":"100","author":"de Alcantara","year":"2021","journal-title":"Adv Clin Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/PTT.S356568","article-title":"Biologics can significantly improve dermatology life quality index (DLQI) in psoriatic patients: A systematic review","volume":"12","author":"de Ruiter","year":"2022","journal-title":"Psoriasis (Auckl)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1017\/S0033291700048017","article-title":"The brief symptom inventory: An introductory report.","volume":"13","author":"Derogatis","year":"1983","journal-title":"Psychol. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology life quality index (DLQI)-a simple practical measure for routine clinical use.","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin. Exp. Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/j.1468-3083.2007.02079.x","article-title":"Psychological distress and coping strategies in patients with psoriasis: The PSYCHAE study.","volume":"21","author":"Finzi","year":"2007","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s40744-023-00602-9","article-title":"Psoriasis and psoriatic arthritis have a major impact on quality of life and depressive symptoms: A cross-sectional study of 300 patients.","volume":"10","author":"Frede","year":"2023","journal-title":"Rheumatol. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis \u2013 oral therapy with a new retinoid.","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e2022332","DOI":"10.23750\/abm.v93i6.13177","article-title":"Epidemiology of psoriasis in Italy: Burden, cost, comorbidities and patients\u2019 satisfaction. A systematic review.","volume":"93","author":"Gianfredi","year":"2022","journal-title":"Acta Biomed."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1111\/bjd.20657","article-title":"Decreased quality of life in people with psoriasis and psoriatic arthritis vs. people with psoriasis alone: Data from a national US survey.","volume":"185","author":"Gondo","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1111\/jdv.15012","article-title":"Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: Results from the Phase 3 VOYAGE 2 study.","volume":"32","author":"Gordon","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis.","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.genhosppsych.2022.01.006","article-title":"Associations between psoriasis and mental illness: An update for clinicians.","volume":"75","author":"Hedemann","year":"2022","journal-title":"Gen. Hosp. Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1111\/bjd.15531","article-title":"Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis.","volume":"177","author":"Iskandar","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","article-title":"Biologic and small-molecule therapies for moderate-to-severe psoriasis: Focus on psoriasis comorbidities.","volume":"37","author":"Jiang","year":"2023","journal-title":"BioDrugs"},{"key":"B23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.22365\/jpsych.2017.281.54","article-title":"Psychological parameters of psoriasis.","volume":"28","author":"Kouris","year":"2017","journal-title":"Psychiatriki"},{"key":"B24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/09546634.2019.1592096","article-title":"The real world impact of adalimumab on quality of life and the physical and psychological effects of moderate-to-severe psoriasis: A UK prospective, multicenter, observational study.","volume":"31","author":"Leman","year":"2020","journal-title":"J. Dermatol. Treatment"},{"key":"B25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/JD9.0000000000000343","article-title":"Effects of biologics on mental health and health-related quality of life in patients with psoriasis: A repeated cross-sectional survey in Chinese population.","volume":"6","author":"Liu","year":"2023","journal-title":"Int. J. Dermatol. Venereol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"115078","DOI":"10.1016\/j.psychres.2023.115078","article-title":"Epidemiology of mental health comorbidity in patients with psoriasis: An analysis of trends from 1986 to 2019.","volume":"321","author":"Liu","year":"2023","journal-title":"Psychiatry Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12964-023-01381-0","article-title":"Triggers for the onset and recurrence of psoriasis: A review and update.","volume":"22","author":"Liu","year":"2024","journal-title":"Cell Commun. Signaling"},{"key":"B28","doi-asserted-by":"publisher","first-page":"109780","DOI":"10.1016\/j.jpsychores.2019.109780","article-title":"Quality of life, anxiety and depressive symptoms in patients with psoriasis: A case-control study.","volume":"124","author":"Mart\u00ednez-Ortega","year":"2019","journal-title":"J. Psychosom. Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/ddg.15251","article-title":"Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment.","volume":"22","author":"Mastorino","year":"2024","journal-title":"J. German Soc. Dermatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1080\/00015550510032832","article-title":"Psychometric properties of the Dermatology life quality index (DLQI) in 900 Italian patients with psoriasis.","volume":"85","author":"Mazzotti","year":"2005","journal-title":"Acta Derm. Venereol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1046\/j.1365-2133.2003.05378.x","article-title":"Sensitivity of the dermatology life quality index to clinical change in patients with psoriasis.","volume":"149","author":"Mazzotti","year":"2003","journal-title":"Br. J. Dermatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3390\/biomedicines10020498","article-title":"Orchestrated cytokines mediated by biologics in psoriasis and its mechanisms of action.","volume":"10","author":"Mohd Noor","year":"2022","journal-title":"Biomedicines"},{"key":"B33","doi-asserted-by":"publisher","first-page":"15528","DOI":"10.1038\/s41598-025-99075-9","article-title":"Cutaneous and systemic improvements in psoriasis patients after different biologic treatments in a real-world longitudinal prospective study.","volume":"15","author":"Ntawuyamara","year":"2025","journal-title":"Sci. Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"102","DOI":"10.5114\/pdia.2015.54873","article-title":"Quality of life and severity of skin changes in the dynamics of Psoriasis.","volume":"33","author":"Owczarek","year":"2016","journal-title":"Postepy Dermatol. Alergol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.1177\/0300060519862658","article-title":"Perceived stress, life events, fatigue and temperament in patients with psoriasis.","volume":"47","author":"Pancar Yuksel","year":"2019","journal-title":"J. Int. Med. Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study.","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"B37","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1080\/00015550510034966","article-title":"Screening for depressive disorders in patients with skin diseases: A comparison of three screeners.","volume":"85","author":"Picardi","year":"2005","journal-title":"Acta Derm. Venereol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.clindermatol.2011.11.006","article-title":"Suicide risk in skin disorders.","volume":"31","author":"Picardi","year":"2013","journal-title":"Clin. Dermatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jaad.2005.11.1103","article-title":"Prevalence and correlates of suicidal ideation among patients with skin disease.","volume":"54","author":"Picardi","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s13555-023-01086-9","article-title":"Comparative effectiveness and durability of biologics in clinical practice: Month 12 outcomes from the international, observational psoriasis study of health outcomes (PSoHO).","volume":"14","author":"Pinter","year":"2024","journal-title":"Dermatol. Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/bjd.20568","article-title":"Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: Results from VOYAGE 1 and VOYAGE 2*.","volume":"185","author":"Reich","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1177\/12034754231204295","article-title":"The mind body connection in dermatologic conditions: A literature review.","volume":"27","author":"Rivers","year":"2023","journal-title":"J. Cutan. Med. Surg."},{"key":"B43","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s40801-023-00359-1","article-title":"Dermatology life quality index in patients with psoriasis treated with biologic versus non-biologic treatment in Malaysia: A retrospective cross-sectional study.","volume":"10","author":"Robinson","year":"2023","journal-title":"Drugs Real World Outcomes"},{"key":"B44","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11136-020-02621-3","article-title":"Comparative study of life satisfaction among patients with psoriasis versus healthy comparison group: The explanatory role of body image and resource profiles.","volume":"30","author":"Rzeszutek","year":"2021","journal-title":"Quality Life Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s10935-024-00784-0","article-title":"Global prevalence of anxiety, depression, and stress among patients with skin diseases: A systematic review and meta-analysis.","volume":"45","author":"Salari","year":"2024","journal-title":"J. Prevent."},{"key":"B46","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/ijd.17387","article-title":"Experience of living with psoriasis in Brazil: A global psoriasis atlas online survey.","volume":"64","author":"Silva","year":"2025","journal-title":"Int. J. Dermatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1159\/000513445","article-title":"Effects of patients\u2019 expectation in dermatology: Evidence from experimental and clinical placebo studies and implications for dermatologic practice and research.","volume":"237","author":"Sondermann","year":"2021","journal-title":"Dermatology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1001\/jama.282.18.1737","article-title":"Validation and utility of a self-report version of PRIME-MD: The PHQ primary care study.","volume":"282","author":"Spitzer","year":"1999","journal-title":"J. Am. Med. Assoc."},{"key":"B49","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2017.08.051","article-title":"Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis longitudinal assessment and registry (PSOLAR).","volume":"78","author":"Strober","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s40257-024-00877-w","article-title":"Association between biologic exposure and the risk of depression in patients with psoriasis: A retrospective analysis of large US administrative claims data.","volume":"25","author":"Strober","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.det.2024.02.007","article-title":"Psoriasis comorbidities and their treatment impact.","volume":"42","author":"Taliercio","year":"2024","journal-title":"Dermatol. Clin."},{"key":"B52","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1017\/S0033291798006667","article-title":"Development of the world health organization WHOQOL-BREF quality of life assessment.","volume":"28","year":"1998","journal-title":"Psychol. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3390\/life13051219","article-title":"Biologic therapies decrease disease severity and improve depression and anxiety symptoms in psoriasis patients.","volume":"13","author":"Timis","year":"2023","journal-title":"Life"},{"key":"B54","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/J.JAD.2024.08.077","article-title":"Efficacy and safety of drugs for psoriasis patients with mental disorders: A systematic review.","volume":"365","author":"Wang","year":"2024","journal-title":"J. Affect. Disord."},{"key":"B55","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jad.2023.05.059","article-title":"Evidence for a causal association between psoriasis and psychiatric disorders using a bidirectional Mendelian randomization analysis in up to 902,341 individuals.","volume":"337","author":"Wang","year":"2023","journal-title":"J. Affect. Disord."},{"key":"B56","doi-asserted-by":"publisher","first-page":"239","DOI":"10.5152\/alphapsychiatry.2023.21723","article-title":"Prevalence of depressive symptoms and their impact on perceived stress and quality of life among patients with psoriasis.","volume":"24","author":"Wannarit","year":"2024","journal-title":"Alpha Psychiatry"},{"key":"B57","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1007\/s13555-024-01302-0","article-title":"Long-term efficacy and safety of bimekizumab and other biologics in moderate to severe plaque psoriasis: Updated systematic literature review and network meta-analysis.","volume":"14","author":"Warren","year":"2024","journal-title":"Dermatol. Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e3263","DOI":"10.1002\/smi.3263","article-title":"Psychosocial stress affects the change of mental distress under dermatological treatment\u2014A prospective cohort study in patients with psoriasis.","volume":"40","author":"Wintermann","year":"2024","journal-title":"Stress Health"},{"key":"B59","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3390\/medicina60010160","article-title":"Exploring the effectiveness of biological therapy in patients with psoriasis: Body image and quality of life.","volume":"60","author":"Wu","year":"2024","journal-title":"Medicina"}],"container-title":["Frontiers in Psychology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyg.2026.1735777\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:37:52Z","timestamp":1770964672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyg.2026.1735777\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":59,"alternative-id":["10.3389\/fpsyg.2026.1735777"],"URL":"https:\/\/doi.org\/10.3389\/fpsyg.2026.1735777","relation":{},"ISSN":["1664-1078"],"issn-type":[{"value":"1664-1078","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"article-number":"1735777"}}